Go Pro

Graham Parry Analyst Performance

Analyst at Citigroup

Graham Parry is a stock analyst at Citigroup in the medical sector, covering 3 publicly traded companies. Over the past year, Graham Parry has issued 1 stock ratings, including and hold recommendations. While full access to Graham Parry's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Graham Parry's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
7 Last 11 Years
Buy Recommendations
28.57% 2 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy28.6%2 ratings
Hold71.4%5 ratings
Sell0.0%0 ratings

Out of 7 total stock ratings issued by Graham Parry at Citigroup, the majority (71.4%) have been Hold recommendations, followed by 28.6% Buy.

Exchange Coverage

ExchangePercentageCount
NYSE
66.7% of companies on NYSE
2 companies
NASDAQ
33.3% of companies on NASDAQ
1 company

Graham Parry, an analyst at Citigroup, currently covers 3 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
100.0%

Graham Parry of Citigroup specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
2 companies
66.7%
MED - BIOMED/GENE
1 company
33.3%

Graham Parry's Ratings History at Citigroup

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
GSK PLC Sponsored ADR stock logo
GSK
GSK
7/24/2026Reiterated Rating$50.78Neutral